Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Sanofi, Dupixent
Sanofi profit growth beats market view on early start of vaccine sales
French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season. Quarterly business operating income,
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), up 14.4% year-over-year and 19.9% in constant currency. The company reported third-quarter sales of 13.
Sanofi posts Q3 revenue beat as Dupixent sales jump
Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full-year earnings guidance. Read more here.
Sanofi Q3 earnings beat market view, boosted by vaccine sales
French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by earlier-than-anticipated sales of seasonal vaccines.
Sanofi Profit Lifted by Early Vaccine Sales, Dupixent Growth
Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy Dupixent.Most Read from BloombergRobotaxis Are No Friend of Public TransportationBooming Cambridge Exposes England’s Widening Wealth GapOman Sees an Urban Future Distinct From Dubai and Abu DhabiArgentina Drug Trafficking Hotspot Sees Murders PlungeClimate Change Is Killing Buildings in Slow MotionEarnings per share excluding some items reached €2.
Dengue is spreading and Sanofi is pulling the US market’s only vaccine. What’s next?
As Sanofi prepares to halt U.S. marketing of its dengue vaccine in 2026, locally acquired infections in the country are raising alarms.
Sanofi Profit, Sales Beat Estimates
The French pharmaceutical company posted better-than-expected earnings and sales in the third quarter, boosted by earlier-than-anticipated flu and respiratory syncytial virus vaccine purchases.
Sanofi shares rise as Q3 results beat forecasts on vaccines and Beyfortus sales
Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, buoyed by strong vaccine revenues and robust early sales of Beyfortus, its respiratory syncytial
1h
on MSN
Sanofi CEO Paul Hudson on Q3 results: The modernization effort is starting to pay off
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, drug pipeline outlook, the ...
4d
Sanofi Pursues Sale Of Painkiller After Political Controversy
Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, ...
STAT
9d
Pharmalittle: We’re reading about generic weight loss drugs, anxiety over a Sanofi deal, and more
India’s powerful copycat pharmaceutical industry is set to roll out generic weight loss drugs in the U.K. within weeks ...
3d
on MSN
Sanofi in Exclusive Talks With CD&R Over Sale of $17 Billion Opella
PARIS (Reuters) -French drugmaker Sanofi said on Monday it had entered exclusive talks to sell a 50% controlling stake in its ...
BioSpace
13d
Sanofi, Denali Abandon Mid-Stage Multiple Sclerosis Study on Disappointing Data
Oditrasertib, which blocks the inflammatory RIPK1 protein, earlier this year also failed a Phase II trial in amyotrophic ...
STAT
8d
Pharmalittle: We’re reading about using Lilly obesity drug to reduce sick days, Sanofi workers striking, and more
The U.K. will study whether Lilly's weight loss drug can get people back to work and help tackle long-term sickness ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback